Harrow Announces First Quarter 2026 Financial Results

First Quarter 2026 and Selected Highlights:  VEVYE® delivered record new and total prescription performance (despite an approximate 18% decline in the overall branded dry eye category) VEVYE demand growth on track to deliver 2026 revenue of over $100 million Quarterly revenue of $44.2 million, including a non-recurring gross-to-net revenue adjustment connected to new VEVYE commercial coverage, which lowered Q1 revenue by approximately $8 million IHEEZO® unit demand increased 18% year-over-year, with 82% of units from retina accounts TRIESENCE® unit demand more than doubled year-over-year, the sixth consecutive quarter of growth Second Quarter revenue expected between $71 million and $81 million Full-year 2026 revenue guidance reaffirmed at $350 million to $365 million Cash and cash equivalents of $94.6 million as of March 31, 2026 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn.